Our Mission & Vision
In recent years we have seen the birth and explosive growth of new and enabling technologies at the interface of microelectronics, materials chemistry, molecular biology and information technology. These new technologies are leading to high performance devices and instruments that find application as test and measurement systems in the service of health and medicine. They find application in such areas as functional genomics (gene discovery), genetic screening, pharmacogenomics (high throughput drug screening and drug discovery), and molecular diagnostics.
Established firmly on such manufacturing principles as miniaturization, modularization, systems integration, parallelism, and redundancy, these technologies promise to vastly reduce the cost of drug development, accelerate the rate of human genomics research, and enable new modes of analysis of analytes not easily measured and at sites previously unprecedented.
Early stage commercial activity has seen the emergence of several high-technology-based start-up companies. A number of these are well funded post IPO (Initial Pubic Offering) companies, while many more are armed with technology licenses, collaborative research agreements, and aggressive R&D; strategies hoping to define their niche in what promises to be a worldwide $B20 market by 2010. As with all rapidly emerging technologies, alliances are being forged between universities, national laboratories and small and large companies.